Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:082800)
South Korea · Delayed Price · Currency is KRW 4,575.00
+105.00 (2.35%)
At close: Feb 6, 2026
Vivozon Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -28,367 | -9,982 | -3,357 | -39,906 | -69,457 | -43,754 |
Depreciation & Amortization | 4,040 | 3,564 | 3,228 | 3,643 | 5,552 | 2,179 |
Loss (Gain) From Sale of Assets | -22.69 | -101.89 | 521 | -278.96 | 229.9 | -337.98 |
Asset Writedown & Restructuring Costs | 1,054 | 1,051 | 32.62 | 6,183 | 35,847 | 10,959 |
Loss (Gain) From Sale of Investments | 107.88 | -7.32 | 812.22 | 1,602 | 13,674 | 14,299 |
Loss (Gain) on Equity Investments | 1,596 | 1,470 | 2,821 | 3,240 | 691.35 | 2,352 |
Stock-Based Compensation | 504.79 | - | - | -51.01 | 277.47 | 195.96 |
Provision & Write-off of Bad Debts | -447.82 | -160.23 | -2,111 | 4,910 | 1,163 | 282.55 |
Other Operating Activities | 11,425 | 10,330 | 5,497 | 13,266 | 3,708 | 12,382 |
Change in Accounts Receivable | -1,463 | -3,228 | -4,419 | -2,278 | -2,734 | 5,141 |
Change in Inventory | -1,451 | -6,912 | -3,665 | 2,750 | -3,756 | 713.04 |
Change in Accounts Payable | -2,282 | 9,484 | 4,719 | 835.48 | -81.21 | -2,840 |
Change in Other Net Operating Assets | 10,329 | 225.08 | -1,088 | 2,760 | -2,611 | 3,052 |
Operating Cash Flow | -4,978 | 5,731 | 2,992 | -3,323 | -17,496 | 4,625 |
Operating Cash Flow Growth | - | 91.57% | - | - | - | - |
Capital Expenditures | -3,307 | -8,450 | -4,523 | -6,491 | -10,111 | -869.36 |
Sale of Property, Plant & Equipment | 12.27 | 89.5 | 9,410 | 645 | -233.64 | 37.06 |
Cash Acquisitions | - | - | - | - | - | -55,252 |
Sale (Purchase) of Intangibles | -2,333 | -2,027 | -2,066 | -2,008 | -1,527 | -327.52 |
Investment in Securities | 4,299 | 6,170 | 13,777 | -26,880 | -24,261 | -7,323 |
Other Investing Activities | -703.31 | -666.68 | 441.38 | -169.41 | -9,196 | 1,832 |
Investing Cash Flow | -2,166 | -6,373 | 19,309 | -34,552 | -47,128 | -64,184 |
Short-Term Debt Issued | - | 1,459 | 7,600 | 4,020 | 18,480 | 1,000 |
Long-Term Debt Issued | - | 3,000 | - | 3,100 | 10,000 | 80,000 |
Total Debt Issued | 7,998 | 4,459 | 7,600 | 7,120 | 28,480 | 81,000 |
Short-Term Debt Repaid | - | -312 | -17,900 | -6,000 | -11,300 | -6,726 |
Long-Term Debt Repaid | - | -3,361 | -6,924 | -28,396 | -1,590 | -5,239 |
Total Debt Repaid | -2,650 | -3,673 | -24,824 | -34,396 | -12,890 | -11,965 |
Net Debt Issued (Repaid) | 5,348 | 786.05 | -17,224 | -27,276 | 15,590 | 69,035 |
Issuance of Common Stock | - | - | 2,059 | 58,171 | 0.02 | - |
Repurchase of Common Stock | - | - | -18.19 | - | - | - |
Other Financing Activities | -1,555 | -1,605 | -1,476 | -4,503 | -2,075 | -1,800 |
Financing Cash Flow | 3,793 | -818.68 | -16,659 | 26,391 | 13,515 | 67,235 |
Foreign Exchange Rate Adjustments | -17.82 | -0.9 | -6.1 | 36.68 | 576.64 | -675.98 |
Net Cash Flow | -3,369 | -1,462 | 5,635 | -11,448 | -50,533 | 7,000 |
Free Cash Flow | -8,285 | -2,719 | -1,532 | -9,814 | -27,608 | 3,755 |
Free Cash Flow Margin | -12.48% | -3.10% | -2.15% | -19.03% | -47.96% | 8.62% |
Free Cash Flow Per Share | -165.54 | -56.95 | -32.10 | -225.59 | -846.59 | 143.39 |
Cash Interest Paid | 1,525 | 1,574 | 1,464 | 3,288 | 1,723 | 1,696 |
Cash Income Tax Paid | 126.89 | 58.28 | -3.43 | -45.67 | 36.03 | 121.5 |
Levered Free Cash Flow | -10,503 | -4,053 | -4,763 | -2,283 | -26,841 | -20,888 |
Unlevered Free Cash Flow | -8,936 | -2,644 | -2,948 | 1,012 | -22,280 | -14,143 |
Change in Working Capital | 5,133 | -431.62 | -4,453 | 4,067 | -9,182 | 6,066 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.